Jerry R Colca
Overview
Explore the profile of Jerry R Colca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colca J, McCommis K
Expert Opin Investig Drugs
. 2025 Feb;
34(1-2):17-26.
PMID: 39912680
Introduction: The concept of insulin resistance has been a major topic for more than 5 decades. While there are several treatments that may impact insulin resistance, this pathology is uniquely...
2.
Colca J, Tanis S, Kletzien R, Finck B
Expert Opin Investig Drugs
. 2023 Sep;
32(9):803-811.
PMID: 37755339
Introduction: 'Insulin sensitizers' derived discoveries of the Takeda Company in 1970s. Pioglitazone remains the best in class with beneficial pleiotropic pharmacology, although use is limited by tolerability issues. Various attempts...
3.
Zhu B, Wei X, Narasimhan H, Qian W, Zhang R, Cheon I, et al.
Sci Immunol
. 2023 Feb;
8(82):eadf0348.
PMID: 36821695
The relationship between diabetes and coronavirus disease 2019 (COVID-19) is bidirectional: Although individuals with diabetes and high blood glucose (hyperglycemia) are predisposed to severe COVID-19, severe acute respiratory syndrome coronavirus...
4.
Ferguson D, Eichler S, Yiew N, Colca J, Cho K, Patti G, et al.
Mol Metab
. 2023 Feb;
70:101694.
PMID: 36801448
Objective: The mitochondrial pyruvate carrier (MPC) has emerged as a therapeutic target for treating insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). We evaluated whether MPC inhibitors (MPCi) might...
5.
Mallet D, Goutaudier R, Barbier E, Carnicella S, Colca J, Fauvelle F, et al.
Mol Neurobiol
. 2022 Jul;
59(10):6170-6182.
PMID: 35895232
A growing body of evidence supports the idea that mitochondrial dysfunction might represent a key feature of Parkinson's disease (PD). Central regulators of energy production, mitochondria, are also involved in...
6.
Colca J, Finck B
Front Mol Biosci
. 2022 Jul;
9:929328.
PMID: 35782864
Alzheimer's (AD) and Parkinson's Diseases (PD) are common neurodegenerative disorders growing in incidence and prevalence and for which there are no disease-modifying treatments. While there are considerable complexities in the...
7.
Peelaerts W, Bergkvist L, George S, Johnson M, Meyerdirk L, Schulz E, et al.
Free Neuropathol
. 2022 Feb;
1.
PMID: 35224554
Epidemiological studies suggest a link between type-2 diabetes and Parkinson's disease (PD) risk. Treatment of type-2 diabetes with insulin sensitizing drugs lowers the risk of PD. We previously showed that...
8.
Colca J, Scherer P
Mol Metab
. 2021 Dec;
55:101409.
PMID: 34863942
Background: Chronic disease appears connected to obesity. However, evidence suggests that chronic metabolic diseases are more specifically related to adipose dysfunction rather than to body weight itself. Scope Of Review:...
9.
Kamm D, Pyles K, Sharpe M, Healy L, Colca J, McCommis K
J Biol Chem
. 2021 May;
296:100807.
PMID: 34022222
Insulin sensitizers and incretin mimetics are antidiabetic agents with vastly different mechanisms of action. Thiazolidinedione (TZD) insulin sensitizers are associated with weight gain, whereas glucagon-like peptide-1 receptor agonists can induce...
10.
Davison B, Harrison S, Cotter G, Alkhouri N, Sanyal A, Edwards C, et al.
J Hepatol
. 2020 Jul;
73(6):1322-1332.
PMID: 32610115
Background & Aims: Liver biopsies are a critical component of pivotal studies in non-alcoholic steatohepatitis (NASH), constituting inclusion criteria, risk stratification factors and endpoints. We evaluated the reliability of NASH...